Drug-Eluting Stent Provides Enhanced Conformability

A novel fully resorbable coronary scaffold system enables cardiologists to address the needs of a broader patient population.

The DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System is a poly-L Lactide (PLLA) based scaffold designed to repair and restore diseased coronary vessels, without the potential risks and complications of a permanent implant. Proprietary fabrication and processing technology allows for the manufacture of a scaffold with excellent flexibility and deliverability, and well-apposed struts that provide substantial radial strength and excellent mechanical support with low recoil, even in highly tortuous vessels.


As a result, the DESolve 100 has a strut profile only 100 µm in diameter, which degrades within one year, returning the patients’ coronary vessel ultimately to its normal de novo state. Other features include self-appositioning to the nominal vessel wall size in cases of malapposition; the ability to maintain radial strength and vessel support for the necessary period of vessel healing while degrading; and the ability to have a wide margin of expansion. The DESolve 100 is a product of Elixir Medical (Sunnyvale, CA, USA), and has received the European Community CE marking of approval.

“Elixir products have become synonymous with dependable and excellent acute performance, and great long-term results,” said Motasim Sirhan, CEO of Elixir Medical. “Elixir is proud to provide physicians with a broad range of products in order to meet their goals of outstanding clinical outcomes for their patients.”

Novolimus is an active metabolite of Sirolimus with antiproliferative and anti-inflammatory properties. Sirolimus is the most widely known mammalian target of rapamycin macrocyclic lactone inhibitor (mTOR), and is used in various treatment applications such as drug eluting stents, transplant, and oncology.

Related Links:
Elixir Medical